Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/karger/rifaximin-in-vitro-and-in-vivo-antibacterial-activity-a-review-MQm0xjTPbd
References (38)
-
William Hoover, E. Gerlach, D. Hoban, G. Eliopoulos, M. Pfaller, Ronald Jones (1993)
Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative.Diagnostic microbiology and infectious disease, 16 2
-
Zhi-Dong Jiang, B. Lowe, Mangala Verenkar, D. Ashley, R. Steffen, N. Tornieporth, F. Sonnenburg, P. Waiyaki, H. Dupont, H. Dupont (2002)
Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay).The Journal of infectious diseases, 185 4
-
H. Dupont, R. Reves, E. Galindo, P. Sullivan, L. Wood, Jaime Mendiola (1982)
Treatment of travelers' diarrhea with trimethoprim/sulfamethoxazole and with trimethoprim alone.The New England journal of medicine, 307 14
-
I. Crossley, E. Wardle, Roger Williams (1983)
Biochemical mechanisms of hepatic encephalopathy.Clinical science, 64 3
-
S. Ripa, F. Mignini, M. Prenna, E. Falcioni (1987)
In vitro antibacterial activity of rifaximin against Clostridium difficile, Campylobacter jejunii and Yersinia spp.Drugs under experimental and clinical research, 13 8
-
H. DuPont, C. Ericsson, J. Mathewson, Ernesto Palazzini, M. Dupont, Zhi-Dong Jiang, A. Mosavi, F. Cabada (1998)
Rifaximin: A Nonabsorbed Antimicrobial in the Therapy of Travelers’ DiarrheaDigestion, 59
-
M. Lucchesi, E. Marchi, Venturini Ap (1984)
Antimycobacterial activity of rifaximin (L/105) in experimental tuberculosis in the guinea pig.Chemioterapia : international journal of the Mediterranean Society of Chemotherapy, 3 6
-
C. Leo, C. Eftimiadi, G. Schito (1986)
Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin.Drugs under experimental and clinical research, 12 12
-
Venturini Ap, E. Marchi (1986)
In vitro and in vivo evaluation of L/105, a new topical intestinal rifamycin.Chemioterapia : international journal of the Mediterranean Society of Chemotherapy, 5 4
-
G. Corazza, Maurizio Ventrucci, A. Strocchi, M. Sorge, L. Pranzo, Raffaele Pezzilli, G. Gasbarrini (1988)
Treatment of Small Intestine Bacterial Overgrowth with Rifaximin, a Non-Absorbable RifamycinJournal of International Medical Research, 16
-
J. Sierra, J. Ruiz, M. Navia, M. Vargas, J. Gascón, J. Vila (2001)
In Vitro Activity of Rifaximin against Enteropathogens Producing Traveler's DiarrheaAntimicrobial Agents and Chemotherapy, 45
-
O. Soro, A. Pesce, Monica Raggi, E. Debbia, G. Schito (1997)
Selection of rifampicin-resistant Mycobacterium tuberculosis does not occur in the presence of low concentrations of rifaximin.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 3 1
-
H. Dupont, H. Dupont, Zhi-Dong Jiang, C. Ericsson, J. Adachi, J. Mathewson, M. Dupont, E. Palazzini, L. Riopel, D. Ashley, Francisco Sandoval (2001)
Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 33 11
-
A. Dell’Anna, P. Azzarone, A. Ferrieri (1999)
A randomized openly comparative study between rifaximin suspension versus rifaximin pills for the eradication of Helicobacter pylori.European review for medical and pharmacological sciences, 3 3
-
P. Brigidi, E. Swennen, Fernando Rizzello, M. Bozzolasco, D. Matteuzzi (2002)
Effects of Rifaximin Administration on the Intestinal Microbiota in Patients with Ulcerative ColitisJournal of Chemotherapy, 14
-
H. Gomi, Zhi-Dong Jiang, J. Adachi, D. Ashley, B. Lowe, Mangala Verenkar, R. Steffen, H. Dupont (2001)
In Vitro Antimicrobial Susceptibility Testing of Bacterial Enteropathogens Causing Traveler's Diarrhea in Four Geographic RegionsAntimicrobial Agents and Chemotherapy, 45
-
A. Lamanna, A. Orsi (1984)
In vitro activity of rifaximin and rifampicin against some anaerobic bacteria.Chemioterapia : international journal of the Mediterranean Society of Chemotherapy, 3 6
-
Bee Ng, Han-Chong Ng, K. Goh, Bow Ho (2001)
Helicobacter pylori in familial clusters based on antibody profile.FEMS immunology and medical microbiology, 30 2
-
M. Amenta, E. Nogare, C. Colomba, T. Prestileo, F. Lorenzo, S. Fundarò, A. Colomba, A. Ferrieri (1999)
Intestinal protozoa in HIV-infected patients: effect of rifaximin in Cryptosporidium parvum and Blastocystis hominis infections.Journal of chemotherapy, 11 5
-
T. Frieden, T. Sterling, A. Pablos-Mendez, J. Kilburn, G. Cauthen, S. Dooley (1993)
The emergence of drug-resistant tuberculosis in New York City.The New England journal of medicine, 328 8
-
Francis Mégraud, F. Bouffant, C. Juncas (1994)
In vitro activity of rifaximin againstHelicobacter pyloriEuropean Journal of Clinical Microbiology and Infectious Diseases, 13
-
C. Eftimiadi, C. Deleo, G. Schito (1984)
Treatment of hepatic encephalopathy with L/105, a new non-absorbable rifamycinDrugs Under Experimental and Clinical Research, 10
-
J. Gillis, R. Brogden (1995)
Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria.Drugs, 49 3
-
(1984)
A: Clinical experience with rifaximin in pediatric diarrhea syndromes -
C. Ericsson, H. DuPont, P. Sullivan, Emma Galindo, Dolores Evans, D. Evans (1983)
Bicozamycin, a poorly absorbable antibiotic, effectively treats travelers' diarrhea.Annals of internal medicine, 98 1
-
J. Adachi, Zhi-Dong Jiang, J. Mathewson, J. Mathewson, Mangala Verenkar, Sharon Thompson, F. Martinez-Sandoval, R. Steffen, C. Ericsson, H. Dupont, H. Dupont (2001)
Enteroaggregative Escherichia coli as a major etiologic agent in traveler's diarrhea in 3 regions of the world.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 32 12
-
R. Steffen, D. Sack, L. Riopel, Zhi-Dong Jiang, M. Stürchler, C. Ericsson, B. Lowe, P. Waiyaki, M. White, H. Dupont (2003)
Therapy of travelers’ diarrhea with rifaximin on various continentsAmerican Journal of Gastroenterology, 98
-
F. Sonnenburg, N. Tornieporth, P. Waiyaki, B. Lowe, L. Peruski, H. Dupont, J. Mathewson, R. Steffen (2000)
Risk and aetiology of diarrhoea at various tourist destinationsThe Lancet, 356
-
A. Venturini (1983)
Pharmacokinetics of L/105, a new rifamycin, in rats and dogs, after oral administration.Chemotherapy, 29 1
-
F. Mignini, E. Falcioni, M. Prenna, F. Santacroce, S. Ripa (1989)
Antibacterial activity of rifaximin against Clostridium difficile, Campylobacter jejunii and Yersinia spp.Journal of chemotherapy, 1 4 Suppl
-
Herbert DuPont, Herbert DuPont, Herbert DuPont, Zhi-Dong Jiang (2004)
Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 10 11
-
H. Neu (1992)
The Crisis in Antibiotic ResistanceScience, 257
-
(1983)
Chemioterapia 1983;2(suppl 5):162–163 -
M. Raviglione, D. Snider, A. Kochi (1995)
Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic.JAMA, 273 3
-
H. DuPont, C. Ericsson, J. Mathewson, F. Cabada, Dennis Conrad (1992)
Oral aztreonam, a poorly absorbed yet effective therapy for bacterial diarrhea in US travelers to Mexico.JAMA, 267 14
-
Zhi-Dong Jiang, S.-S. Ke, E. Palazzini, L. Riopel, H. Dupont (2000)
In Vitro Activity and Fecal Concentration of Rifaximin after Oral AdministrationAntimicrobial Agents and Chemotherapy, 44
-
A. Marchese, A. Salerno, A. Pesce, E. Debbia, G. Schito (2000)
In vitro Activity of Rifaximin, Metronidazole and Vancomycin against Clostridium difficile and the Rate of Selection of Spontaneously Resistant Mutants against Representative Anaerobic and Aerobic Bacteria, Including Ammonia-Producing SpeciesChemotherapy, 46
-
(1983)
L / 105 , a new semisynthetic derivative of rifamycin SV , synthesis and structure - activity relationship
- Publisher
- Karger
- Copyright
- © 2005 S. Karger AG, Basel
- ISSN
- 0009-3157
- eISSN
- 1421-9794
- DOI
- 10.1159/000081991
- Publisher site
- See Article on Publisher Site
Abstract
In vitro inhibitory activity of rifaximin is directed against Gram-positive and Gram-negative, aerobic and anaerobic bacteria. It is effective in the treatment of gastrointestinal infections when given orally because of the high concentration of the drug remaining in the gut lumen. Laboratory investigations have been carried out to assess the in vitro activity of rifaximin on different bacterial strains isolated from both human and domestic animals. The objective of this project is to review the in vitro and in vivo activity of rifaximin against bacterial infection with Gram-negative rods, Gram-positive rods and Gram-positive cocci and their resistance to rifaximin. The available data suggest that rifaximin is active in vitro and in vivo in the treatment of bacterial infection of adults and children.
Journal
Chemotherapy – Karger
Published: Apr 1, 2005
Keywords: Antibacterial activity; Gram-positive bacteria; Gram-negative bacteria; Rifaximin